Document is current
Any future updates will be listed below
-
Authors
Phillips, Mark R. http://orcid.org/0000-0003-0923-261X
Steel, David H.
Wykoff, Charles C.
Busse, Jason W.
Bannuru, Raveendhara R. http://orcid.org/0000-0002-8069-5783
Thabane, Lehana http://orcid.org/0000-0003-0355-9734
Bhandari, Mohit http://orcid.org/0000-0001-9608-4808
Chaudhary, Varun http://orcid.org/0000-0002-9988-4146
,
Sivaprasad, Sobha
Kaiser, Peter
Sarraf, David
Bakri, Sophie J.
Garg, Sunir J.
Singh, Rishi P.
Holz, Frank G.
Wong, Tien Y.
Guymer, Robyn H.
- License Information
-
More Information
Article History
Received: 2 January 2022
Revised: 7 January 2022
Accepted: 17 January 2022
First Online: 10 February 2022
Competing interests
: MRP: Nothing to disclose. DHS: Consultant: Gyroscope, Roche, Alcon, BVI; Research Funding for IIS: Alcon, Bayer, DORC, Gyrsocope, Boehringer-Ingelheim – unrelated to this study. CCW: Consultant: Acuela, Adverum Biotechnologies, Inc, Aerpio, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, Bayer AG, Chengdu Kanghong Pharmaceuticals Group Co, Ltd, Clearside Biomedical, DORC (Dutch Ophthalmic Research Center), EyePoint Pharmaceuticals, Gentech/Roche, GyroscopeTx, IVERIC bio, Kodiak Sciences Inc, Novartis AG, ONL Therapeutics, Oxurion NV, PolyPhotonix, Recens Medical, Regeron Pharmaceuticals, Inc, REGENXBIO Inc, Santen Pharmaceutical Co, Ltd, and Takeda Pharmaceutical Company Limited; Research funds: Adverum Biotechnologies, Inc, Aerie Pharmaceuticals, Inc, Aerpio, Alimera Sciences, Allergan, Apellis Pharmaceuticals, Chengdu Kanghong Pharmaceutical Group Co, Ltd, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Inc, GyroscopeTx, Ionis Pharmaceuticals, IVERIC bio, Kodiak Sciences Inc, Neurotech LLC, Novartis AG, Opthea, Outlook Therapeutics, Inc, Recens Medical, Regeneron Pharmaceuticals, Inc, REGENXBIO Inc, Samsung Pharm Co, Ltd, Santen Pharmaceutical Co, Ltd, and Xbrane Biopharma AB – unrelated to this study. JWB: Nothing to disclose. RRB: Research funds: Pfizer – unrelated to this study. LT: Nothing to disclose. MB: Research funds: Pendopharm, Bioventus, Acumed – unrelated to this study. VC: Advisory Board Member: Alcon, Roche, Bayer, Novartis; Grants: Bayer, Novartis – unrelated to this study.
Free to read: This content has been made available to all.
